T — primary tumour (Breslow thickness / ulceration)
T1a — < 0.8 mm, no ulceration
T1b — < 0.8 mm with ulceration, or 0.8–1.0 mm (± ulceration)
T2a — > 1.0 to 2.0 mm, no ulceration
T2b — > 1.0 to 2.0 mm, ulcerated
T3a — > 2.0 to 4.0 mm, no ulceration
T3b — > 2.0 to 4.0 mm, ulcerated
T4a — > 4.0 mm, no ulceration
T4b — > 4.0 mm, ulcerated
N — regional nodes / in-transit disease
N0 — no regional node or in-transit disease
N1a — 1 clinically occult node (detected by sentinel biopsy)
N1b — 1 clinically detected node
N1c — no nodes, but microsatellite / satellite / in-transit metastasis
N2a — 2–3 clinically occult nodes
N2b — 2–3 nodes, at least one clinically detected
N2c — 1 node (occult or detected) plus in-transit / satellite disease
N3a — ≥ 4 clinically occult nodes
N3b — ≥ 4 nodes (≥ 1 detected), or any matted nodes
N3c — ≥ 2 nodes and/or matted nodes, plus in-transit / satellite disease
Evidence
[1] Original publication
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the AJCC eighth-edition cancer staging manual. T1 was split at 0.8 mm, mitotic rate was removed from T staging, N categories were expanded for microsatellites/in-transit disease, and M1d (CNS) was added; stage III was resolved into IIIA–IIID.
CA: A Cancer Journal for Clinicians, 2017
[2] Guideline
Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual, 8th edition (print manual, no PubMed record).
Springer, 2017
[3] Note on this tool
This tool uses the pathological stage table; the clinical stage table differs. The stage III sub-groups are intricate — confirm against the manual.
Last reviewed: 2026-10
Report an error in this calculator